Archive for November 11th, 2008

Chemistry and Industry - Crestor takes heart.(Letters)(Letter to the editor)

Tuesday, November 11th, 2008

The METEOR trial examined AstraZeneca’s Crestor (rosuvastatin) in patients with early signs of atherosclerosis. C&I notes that because the METEOR study did not show regression of atherosclerosis, it ‘dashes hopes for an expanded label’ (C&I 2007, 7, 7). While METEOR did not show regression, this was not its primary endpoint.

Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
…